BioLife Solutions, Inc. (BLFS)

NCM – Цена в реальном времени. Валюта: USD

28.67

+1.17 (4.25%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

30.55

+1.88 (6.56%)

После закрытия: Jun 26, 2026, 7:58 PM EDT

08.05.2026

BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript

08.05.2026

BioLife Solutions, Inc. (BLFS) Tops Q1 Earnings and Revenue Estimates

BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.04 per share a year ago.

07.05.2026

BioLife Solutions Reports First Quarter 2026 Financial Results

Total revenue of $27.5 million, up 25% over Q1 2025 GAAP gross margin and non-GAAP adjusted gross margin of 64% GAAP net income of $1.2 million and non-GAAP adjusted EBITDA of $6.2 million or 22% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash.

27.04.2026

4 Medical Product Stocks to Buy From a Challenging Industry

The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.

23.04.2026

BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

BOTHELL, Wash., April 23, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2026 first quarter financial results will be released on May 7, 2026.

21.04.2026

BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase

Award Recognizes Technologies That Address Important Industry Needs and Advance Prior Standards BOTHELL, Wash., April 21, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced it has received the INTERPHEX 2026 Biotech Innovation Award for its CellSeal® CryoCase, a rigid cryogenic containment system purpose-built for frozen biologic materials.

08.04.2026

Wall Street Analysts Think BioLife Solutions (BLFS) Could Surge 70.78%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 70.8% in BioLife Solutions (BLFS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Видео

No Data

There is no data to display

Пресс-релизы

07.05.2026

BioLife Solutions Reports First Quarter 2026 Financial Results

21.04.2026

BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase

26.02.2026

BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations

Fourth quarter 2025 revenue from continuing operations of $24.8 million, up 20% year-over-year; Full year 2025 revenue of $96.2 million, up 29% year-over-year GAAP gross margin of 63% and non-GAAP adjusted gross margin of 64% for the fourth quarter GAAP net income of $2.1 million or $0.04 per share and adjusted EBITDA of $6.9 million, or 28% of total revenue for the fourth quarter Expects 2026 revenue growth of $112.5 million to $115.0 million, up 17%-20% over 2025 Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash.

12.02.2026

BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market

BOTHELL, Wash., Feb. 12, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces it has entered into a multi-year supply agreement with Qkine Limited under which BioLife will distribute certain cytokine and growth factor products manufactured by Qkine for use in cell and gene therapy manufacturing.

BioLife Solutions, Inc. (BLFS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

BioLife Solutions, Inc. (BLFS)

BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript

BioLife Solutions, Inc. (BLFS) Tops Q1 Earnings and Revenue Estimates

BioLife Solutions Reports First Quarter 2026 Financial Results

4 Medical Product Stocks to Buy From a Challenging Industry

BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase

Wall Street Analysts Think BioLife Solutions (BLFS) Could Surge 70.78%: Read This Before Placing a Bet

Видео

No Data

Пресс-релизы

BioLife Solutions Reports First Quarter 2026 Financial Results

BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase

BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations

BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market

BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript

BioLife Solutions, Inc. (BLFS) Tops Q1 Earnings and Revenue Estimates

BioLife Solutions Reports First Quarter 2026 Financial Results

4 Medical Product Stocks to Buy From a Challenging Industry

BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase

Wall Street Analysts Think BioLife Solutions (BLFS) Could Surge 70.78%: Read This Before Placing a Bet

Видео

No Data

Пресс-релизы

BioLife Solutions Reports First Quarter 2026 Financial Results

BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase

BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations

BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market

Search stocks

BioLife Solutions, Inc. (BLFS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

BioLife Solutions, Inc. (BLFS)

BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript

BioLife Solutions, Inc. (BLFS) Tops Q1 Earnings and Revenue Estimates

BioLife Solutions Reports First Quarter 2026 Financial Results

4 Medical Product Stocks to Buy From a Challenging Industry

BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase

Wall Street Analysts Think BioLife Solutions (BLFS) Could Surge 70.78%: Read This Before Placing a Bet

Видео

No Data

Пресс-релизы

BioLife Solutions Reports First Quarter 2026 Financial Results

BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase

BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations

BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market

BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript

BioLife Solutions, Inc. (BLFS) Tops Q1 Earnings and Revenue Estimates

BioLife Solutions Reports First Quarter 2026 Financial Results

4 Medical Product Stocks to Buy From a Challenging Industry

BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase

Wall Street Analysts Think BioLife Solutions (BLFS) Could Surge 70.78%: Read This Before Placing a Bet

Видео

No Data

Пресс-релизы

BioLife Solutions Reports First Quarter 2026 Financial Results

BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase

BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations

BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market